ERBB2 and neoplasm: We found that ganetespib remarkably inhibited ErbB2-overexpressing tumor growth with an average final tumor volume of 922.8 ± 291.7 mm3 in the ganetespib-treated mice versus 2848.6 ± 489.6 mm3 in the control mice (Fig. 7).